scholarly journals Inhibition of STAT3 activation mediated by toll‐like receptor 4 attenuates angiotensin II‐induced renal fibrosis and dysfunction

2019 ◽  
Vol 176 (14) ◽  
pp. 2627-2641 ◽  
Author(s):  
Zheng Xu ◽  
Chunpeng Zou ◽  
Weihui Yu ◽  
Sujing Xu ◽  
Lan Huang ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Renal Fibrosis ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4

scholarly journals Angiotensin II Upregulates Toll-Like Receptor 4 on Mesangial Cells

2006 ◽  
Vol 17 (6) ◽  
pp. 1585-1593 ◽  
Author(s):  
Gunter Wolf ◽  
Jürgen Bohlender ◽  
Tzvetanka Bondeva ◽  
Thierry Roger ◽  
Friedrich Thaiss ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Mesangial Cells ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4

Toll-like receptor 4 (TLR4) impairs nitric oxide contributing to Angiotensin II-induced cavernosal dysfunction

Life Sciences ◽  
2017 ◽  
Vol 191 ◽  
pp. 219-226 ◽  
Author(s):  
Kenia P. Nunes ◽  
Gisele F. Bomfim ◽  
Haroldo A. Toque ◽  
Theodora Szasz ◽  
R. Clinton Webb
Keyword(s):  
Nitric Oxide ◽  
Angiotensin Ii ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4

scholarly journals Toll‐Like Receptor 4 Contributes to Hypertension and Endothelial Dysfunction Produced By Angiotensin II

2012 ◽  
Vol 26 (S1) ◽  
Author(s):  
Vijay Palvia ◽  
Chelsea Pyle ◽  
Erin Mezzetti ◽  
Xunsheng Chen ◽  
Sean Didion
Keyword(s):  
Angiotensin Ii ◽  
Endothelial Dysfunction ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4

scholarly journals Diabetic Nephropathy Progression in type 1 Diabetes: Temporal Renal Angiopoietin-Like Protein 2-Toll-Like Receptor 4 and Role of Early Renal Angiotensin II Inhibition by Valsartan

2021 ◽  
Author(s):  
Mona K. Tawfik ◽  
mohammed keshawy ◽  
Samy Makary
Keyword(s):  
Blood Pressure ◽  
Diabetic Nephropathy ◽  
Angiotensin Ii ◽  
Kidney Injury ◽  
Diabetic Rats ◽  
Vehicle Group ◽  
Ang Ii ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Urine Albumin

Abstract Diabetic nephropathy (DN) is a consequence of diabetes mellitus (DM). DM is associated temporal changes in renal angiotensin II (ANG II) release and multiple mediators leading to DN. These changes were evaluated using early ANG II blocker valsartan as a DN renoprotective drug. Adult male Wister rats were divided into (i) vehicle group; (ii) valsartan received oral 30 mg/Kg/day; (iii) diabetic received single 50 mg/Kg intraperitoneal streptozotocin injection; (iv) renoprotection, valsartan treated-diabetic rats after 7 days from DM. Other group of diabetic animals assigned to receive late valsartan intervention from week 9 to 12 of DM. The renoprotective effect evaluated at 4th, 8th, 12th weeks. DN effects on urine albumin excretion, blood pressure and renal ANG II were measured. Urinary nephrin and kidney injury molecule-1 biomarkers, renal ANGPTL2, and toll-like receptor 4 (TLR 4) mRNA expression were tested. DN-initiated fibrotic markers integrin, α-smooth muscle expression and collagen IV and apoptotic protein caspase 3 were tested. DM induced changes starting from the 4th week. At 12th week, early valsartan intervention showed a significant reduction in ANG II, ANGPTL2 and TLR 4 expression and improvement in albuminuria, blood pressure, urinary biomarkers, fibrotic and apoptotic markers, more than the late intervention. Early inhibition of ANG II in diabetes is associated with decrease in ANGPTL2 and TLR 4 proteins and fibrotic changes. This observation helps in understanding DN pathophysiology and its therapeutic approaches.

Lectin-Like ox-LDL Receptor-1 (LOX-1)–Toll-Like Receptor 4 (TLR4) Interaction and Autophagy in CATH.a Differentiated Cells Exposed to Angiotensin II

2014 ◽  
Vol 51 (2) ◽  
pp. 623-632 ◽  
Author(s):  
Zufeng Ding ◽  
Shijie Liu ◽  
Xianwei Wang ◽  
Magomed Khaidakov ◽  
Yao Dai ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Ldl Receptor ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Differentiated Cells
Sign in / Sign up

Export Citation Format

Share Document